Compare Quest Diagnostics Inc (DGX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Under Armour Inc Class A — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Quest Diagnostics Inc is far larger — about 12.3× Under Armour Inc Class A's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Under Armour Inc Class A for 99 Days on average.
| DGX | UAA | |
|---|---|---|
Market Cap | $25.48B | $2.07B |
Volume | 941,866 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $8.14 |
52-Week Low | $173.49 | $4.17 |
Typical Hold Time | 56 Days | 99 Days |
Enterprise Value | $31.23B | $3.05B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Under Armour (UAA) trades at $4.88, up 1.24% with a mixed technical picture showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with negative net income margins (-9.99%) and declining revenue trends, though valuation metrics like P/S (0.42) appear attractive. Recent news highlights brand transformation efforts amid softer demand, with the company maintaining profitability outlook despite revenue cuts.
The outlook remains cautious with significant execution risks as Under Armour navigates weak consumer spending. Analyst consensus shows modest upside to the $5.79 price target, but persistent revenue declines and negative cash flow trends pose substantial headwinds for shareholder value recovery in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
